| [1] |
Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2016, 34(21):2541-2556.
|
| [2] |
Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2016, 34(22):2654-2668.
|
| [3] |
Sohal DP, Mangu PB, Khorana AA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2016, 34(23):2784-2796.
|
| [4] |
Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)[J]. Surgery, 2014, 155(6):977-988.
|
| [5] |
Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: the new R-status counts[J]. Ann Surg, 2017, 265(3):565-573.
|
| [6] |
Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis[J]. J Clin Oncol, 2017, 35(5):515-522.
|
| [7] |
de Geus SW, Eskander MF, Bliss LA, et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma:a nationwide propensity score matched analysis[J]. Surgery, 2017, 161(3):592-601.
|
| [8] |
陈汝福，周泉波．胰头癌行根治性胰十二指肠切除术神经清扫指征与技巧[J]．中国实用外科杂志，2016,36(8):847-850.
|
| [9] |
Lin Q, Tan L, Zhou Y, et al. Radical nerve dissection for the carcinoma of head of pancreas: report of 30 cases[J]. Chin J Cancer Res, 2016, 28(4):429-434.
|
| [10] |
陈汝福，周泉波．神经周围浸润在胰腺癌患者预后中的意义[J/CD]．中华肝脏外科手术学电子杂志，2014,3(2):71-73.
|
| [11] |
Strobel O, Hinz U, Gluth A, et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories[J]. Ann Surg, 2015, 261(5):961-969.
|
| [12] |
Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional validation study of the American Joint Commission on Cancer (8th Edition) Changes for T and N staging in patients with pancreatic adenocarcinoma[J]. Ann Surg, 2017, 265(1):185-191.
|
| [13] |
Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis[J]. Lancet Oncol, 2016, 17(6):801-810.
|
| [14] |
Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients[J]. Ann Surg, 2016, 264(3):457-463.
|
| [15] |
Scheffer HJ, Nielsen K, de Jong MC, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy[J]. J Vasc Interv Radiol, 2014, 25(7):997-1011.
|
| [16] |
Martin RC 2nd, Kwon D, Chalikonda S, et al. Treatment of 200 locally advanced (stage Ⅲ) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy[J]. Ann Surg, 2015, 262(3):486-494.
|
| [17] |
Chang DK, Grimmond SM, Evans TR, et al. Mining the genomes of exceptional responders[J]. Nat Rev Cancer, 2014, 14(5):291-292.
|
| [18] |
Hurwitz HI, Uppal N, Wagner SA, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed[J]. J Clin Oncol, 2015, 33(34):4039-4047.
|
| [19] |
Massó-Vallés D, Jauset T, Serrano E, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma[J]. Cancer Res, 2015, 75(8):1675-1681.
|
| [20] |
Soares KC, Rucki AA, Wu AA, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors[J]. J Immunother, 2015, 38(1):1-11.
|